RxDoctor Payments Data

Marianna Cardenas-Fernandez, MD

Family Medicine · Lubbock, TXNPI 1851957989

Payments from drug & device makers

$3,048in general payments, 2019–2025

Across 68 payments — averaging $44.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$645
  • AstraZeneca$442
  • Abbott$308
  • Teva Pharmaceuticals USA, Inc.$284
  • Astellas Pharma US Inc$224
  • Lilly USA, LLC$186
  • plus $959 from 11 others

What the payments were for

  • Food & beverage$3,048100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,048 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$26,745
Medicare patients
92
Services billed
492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol17$24,266
JardianceEmpagliflozin21$20,275
OzempicSemaglutide11$10,547
Duloxetine Hcl35$1,088
Diclofenac Potassium34$678
Levothyroxine Sodium56$591
Atorvastatin Calcium59$426
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen18$422
Gabapentin35$415
Aripiprazole14$323
Fluticasone Propionate19$318
Rosuvastatin Calcium21$311
Losartan Potassium20$269
Lisinopril59$240
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav23$234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$442$24,26617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →